Top Line: We’ve got the answers to most any question that might arise in a multidisciplinary setting when discussing the option for SABR as definitive management of RCC.
The Study: This comprehensive Q&A-style review synthesizes contemporary evidence and guidelines on stereotactic ablative radiation therapy (SABR) for localized renal cell carcinoma (RCC), now firmly guideline-endorsed for those who are medically inoperable or surgery-averse. Prospective trials and pooled analyses demonstrate >95% 5-year local control with low rates of grade 3+ events and modest decline in estimated glomerular filtration rates. SABR outperforms thermal ablation in both evidence depth and breadth of indications including larger (≥4 cm), central, or peri-hilar tumors. Dose schemas (26 Gy ×1, 42 Gy ×3, or ~40–50 Gy ×5) are tailored to size and proximity or organs at risk, with planning emphasizing minimization of intermediate-dose spill to preserve renal function. Applications extend to solitary kidneys, larger T2 lesions, salvage after failed ablation, and even investigational roles in IVC thrombus and cytoreduction.
TBL: SABR has undoubtedly transitioned from investigational to guideline-backed standard for non-surgical definitive management of RCC. | Correa, Int J Radiat Oncol Biol Phys 2026
The Study: This comprehensive Q&A-style review synthesizes contemporary evidence and guidelines on stereotactic ablative radiation therapy (SABR) for localized renal cell carcinoma (RCC), now firmly guideline-endorsed for those who are medically inoperable or surgery-averse. Prospective trials and pooled analyses demonstrate >95% 5-year local control with low rates of grade 3+ events and modest decline in estimated glomerular filtration rates. SABR outperforms thermal ablation in both evidence depth and breadth of indications including larger (≥4 cm), central, or peri-hilar tumors. Dose schemas (26 Gy ×1, 42 Gy ×3, or ~40–50 Gy ×5) are tailored to size and proximity or organs at risk, with planning emphasizing minimization of intermediate-dose spill to preserve renal function. Applications extend to solitary kidneys, larger T2 lesions, salvage after failed ablation, and even investigational roles in IVC thrombus and cytoreduction.
TBL: SABR has undoubtedly transitioned from investigational to guideline-backed standard for non-surgical definitive management of RCC. | Correa, Int J Radiat Oncol Biol Phys 2026